Search clinical trials for: ATx201 Gel 4%

Total 7036 results

UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Pfizer

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Pharma Holdings AS
CTC Clinical Trial Consultants AB

Completed

Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Nasal Decolonization of Staphylococcus Aureus

Sweden
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Pompe Disease Infantile-Onset

Taiwan, United States, Italy
Novan, Inc.

Completed

A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne

Acne Vulgaris

Dominican Republic, Honduras, Panama
Novan, Inc.

Completed

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

Acne Vulgaris

United States
Memorial University of Newfoundland

Recruiting

Biofreeze and the Effect on Knee Osteoarthritis

Knee Osteoarthritis

Canada
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Enrolling by invitation

A Long-term Follow-up Study in Participants Who Received CTX001

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Canada, Italy, United Kingdom, Germany
Novan, Inc.

Completed

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers

Acne Vulgaris

United States
Novan, Inc.
Chiltern International Inc.

Completed

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

Acne Vulgaris

United States
Novan, Inc.
Chiltern International Inc.

Completed

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

Acne Vulgaris

United States
National Taiwan University Hospital

Unknown

Ventilation Efficacy of Size 3 or Size 4 I-gel in Female Patient Weighing 50 to 60 Kilograms

Breast Neoplasms | Body Weight | Laryngeal Masks

Taiwan
Novan, Inc.

Completed

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
RegeneRx Biopharmaceuticals, Inc.
sigma-tau i.f.r. S.p.A.

Completed

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers (SSVS)

Venous Stasis Ulcers

Italy, Poland
Organon and Co

Completed

The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)

Osteoarthritis Pain
Novan, Inc.

Completed

SB208 for the Treatment of Tinea Pedis

Tinea Pedis

Dominican Republic
Novan, Inc.
Premier Research Group plc

Completed

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

Molluscum Contagiosum

United States
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases | Hydroxyurea Failure | Hydroxyurea Intolerance

United States, Italy, United Kingdom, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases

United States, Belgium, Canada, France, Germany, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, United Kingdom, Germany, Canada, Italy
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
AlgoTherapeutix

Recruiting

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (ACT)

Chemotherapy-induced Peripheral Neuropathy

United States, Spain, Belgium, France, Czechia, Poland, Italy
UNION therapeutics

Completed

Evaluation of ATx201 as a Topical Antibiotic Agent

Infection, Bacterial

Austria
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Amy C. Degnim
National Cancer Institute (NCI)

Recruiting

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ

Breast Atypical Lobular Hyperplasia | Breast Atypical Hyperplasia | Breast Lobular Carcinoma in Situ

United States
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Phramongkutklao College of Medicine and Hospital

Active, not recruiting

Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand

Ivermectin | School-age Children | Pediculus Capitis Infestation | Permethrin Adverse Reaction | Dimethicone Adverse Reaction | Permethrin Allergy | Dimethicone Allergy

Thailand
Zonguldak Bulent Ecevit University

Completed

Effect of Different Supralottic Airway Devicess on Optic Nerve Sheath Diameter

Intracranial Pressure Increase | Supraglottic Airway Device | Optic Nerve Sheath Diameter

Turkey
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Dravet Syndrome

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (ENDEAVOR)

Dravet Syndrome

United States
Coeptis Therapeutics
Fred Hutchinson Cancer Center

Completed

Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

COVID-19 Pneumonia

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
Seaside Therapeutics, Inc.

Completed

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

Fragile X Syndrome

United States
Amicus Therapeutics

Terminated

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Type 1 Gaucher Disease

United States, United Kingdom
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (UK Only)

Dravet Syndrome

United Kingdom
Xilio Development, Inc.

Recruiting

XTX301 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Almac Discovery

Terminated

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Ovarian Cancer | Solid Tumors

United Kingdom
Seaside Therapeutics, Inc.

Completed

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Fragile X Syndrome

United States
University of Oklahoma

Withdrawn

Functional Microarray Augmentation of Skin Treatment With Lidocaine (FAST)

Pain Perception | Phlebotomy

United States
University of Massachusetts, Worcester

Completed

Intratumoral Injection Of Alpha-Gal Glycosphingolipids

Metastatic Melanoma

United States

Search clinical trials for: ATx201 Gel 4%

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations